Diclofenac (Voltaren)
diclofenac sodium & diclofenac potassium
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Osteoarthritis | Adults | Monotherapy | FDA Approved |
| Rheumatoid arthritis | Adults | Monotherapy or adjunctive with DMARDs | FDA Approved |
| Ankylosing spondylitis | Adults | Monotherapy | FDA Approved |
| Acute pain & primary dysmenorrhea | Adults (diclofenac potassium IR) | Monotherapy | FDA Approved |
| Acute migraine with or without aura | Adults (Cambia oral solution) | Monotherapy | FDA Approved |
| OA of accessible joints (topical) | Adults (Voltaren Gel 1%) | Monotherapy (topical) | FDA Approved |
Diclofenac is one of the most widely prescribed NSAIDs globally, available in an extensive range of oral, topical, ophthalmic, and injectable formulations. As a phenylacetic acid derivative, it is a potent non-selective inhibitor of both COX-1 and COX-2, with somewhat greater affinity for COX-2 than some traditional NSAIDs. Its short plasma half-life (~2 hours) belies its clinical duration of action, as diclofenac persists in synovial fluid well beyond plasma clearance. Diclofenac carries a notably higher hepatotoxicity risk than other NSAIDs, with transaminase elevations >3× ULN observed in approximately 2% of patients — mandating periodic LFT monitoring during chronic therapy. The CNT Collaboration meta-analysis found that diclofenac 150 mg/day carried cardiovascular risk comparable to COX-2 selective inhibitors.
Renal colic — IM diclofenac 75 mg is widely used as first-line treatment for acute renal colic, supported by multiple randomised trials and Cochrane review evidence. Evidence quality: High.
Post-operative pain (multimodal) — Oral or IM diclofenac is commonly incorporated into multimodal analgesia protocols for opioid-sparing postoperative management. Evidence quality: High.
Chronic low back pain — NSAIDs including diclofenac are recommended as first-line pharmacotherapy by ACP guidelines for acute and chronic low back pain. Evidence quality: Moderate.
Dosing
Adult Oral Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Osteoarthritis — chronic management | 50 mg BID–TID or 75 mg BID (DR tablets) | 100–150 mg/day in divided doses | 150 mg/day | Voltaren XR 100 mg once daily is an alternative for OA Use lowest effective dose for shortest duration |
| Rheumatoid arthritis — active disease | 50 mg TID–QID or 75 mg BID (DR tablets) | 150–200 mg/day in divided doses | 200 mg/day | Does not alter disease course; use alongside DMARDs Monitor LFTs within 4–8 weeks of initiation |
| Ankylosing spondylitis | 25 mg QID + additional 25 mg at bedtime if needed | 100–125 mg/day | 125 mg/day | Enteric-coated formulation preferred for chronic use Assess response before exceeding 100 mg/day |
| Acute pain / primary dysmenorrhea | 50 mg TID (diclofenac potassium) | 50 mg TID | 150 mg/day | Diclofenac potassium (Cataflam) provides faster onset than enteric-coated sodium salt; initial dose of 100 mg may be given for dysmenorrhea Short-term use recommended |
| Acute migraine (Cambia oral solution) | 50 mg single dose | Single dose only | 50 mg/attack | Dissolve powder in 30–60 mL of water; not for prophylaxis Rapid absorption formulation; Tmax ~15 min |
Diclofenac sodium enteric-coated (DR) tablets have a delayed Tmax (1–4.5 h lag) due to the enteric coating — they are designed for chronic inflammatory conditions, not rapid pain relief. Diclofenac potassium (Cataflam) is formulated for immediate release with faster absorption, making it appropriate for acute pain. Voltaren XR (100 mg) provides once-daily convenience but is only approved for OA and RA. Different salt forms and formulations are not interchangeable at the same milligram strength.
Special Population Adjustments
| Population | Adjustment | Rationale |
|---|---|---|
| Hepatic impairment | May need dose reduction; initiate at lowest dose | Hepatic metabolism accounts for nearly 100% of elimination; higher hepatotoxicity risk than other NSAIDs |
| Renal impairment (mild–moderate) | No dose adjustment necessary | Unchanged diclofenac is not significantly renally eliminated; however, conjugate metabolites may accumulate in severe impairment |
| Advanced renal disease | Not recommended | May hasten progression of renal dysfunction |
| Elderly (≥65 years) | Start at lowest effective dose | Increased risk of GI, CV, renal, and hepatic adverse events |
Pharmacology
Mechanism of Action
Diclofenac is a phenylacetic acid derivative that inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis at sites of inflammation, pain, and fever. Among traditional NSAIDs, diclofenac has somewhat greater relative affinity for COX-2 than agents like naproxen or ibuprofen, though it is not considered a selective COX-2 inhibitor. This intermediate selectivity profile may contribute to both its clinical efficacy and its cardiovascular risk pattern, which the CNT meta-analysis found to be comparable to coxibs. Additionally, diclofenac has been shown to inhibit the lipoxygenase pathway and reduce leukotriene production, which may contribute to its anti-inflammatory potency beyond COX inhibition alone.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | 100% absorbed orally; ~50% systemically available due to extensive first-pass metabolism; Tmax ~1 h (IR/potassium salt); enteric-coated: 1–4.5 h lag before absorption begins; food delays onset but does not affect total absorption | Choose potassium salt for rapid-onset pain relief (Tmax ~1 h); enteric coating causes variable lag time; 50% bioavailability is clinically significant — the effective dose is already accounted for in PI dosing |
| Distribution | V/F 1.4 L/kg; >99% albumin-bound; penetrates and persists in synovial fluid (reversal of gradient after plasma levels decline) | Despite short plasma half-life, synovial fluid persistence supports 2–3× daily dosing for arthritis; active accumulation in inflamed joints contributes to clinical efficacy |
| Metabolism | Hepatic (~100%): CYP2C9 hydroxylation to 4’-hydroxy-diclofenac (major metabolite), plus 5-hydroxy and 3’-hydroxy metabolites; UGT2B7 glucuronidation; all metabolites have minimal pharmacological activity | Nearly complete hepatic dependence makes diclofenac uniquely hepatotoxicity-prone among NSAIDs; CYP2C9 polymorphisms may alter clearance; caution with hepatotoxic co-medications |
| Elimination | t½ ~2 h (unchanged drug); ~65% urine, ~35% bile (as conjugated metabolites); little or no unchanged drug in urine; no accumulation with repeated dosing | Short half-life limits accumulation risk; no dose adjustment for mild–moderate renal impairment since unchanged drug is not renally cleared; conjugate metabolites may accumulate in severe renal failure |
Side Effects
Diclofenac produces adverse effects (particularly gastrointestinal) in approximately 20% of patients. Hepatotoxicity is notably more frequent with diclofenac than with other NSAIDs: in clinical trials of ~5,700 patients, meaningful AST elevations (>3× ULN) occurred in about 2%. In an open-label trial of 3,700 patients treated for 2–6 months, ALT/AST elevations occurred in ~4% and marked elevations (>8× ULN) in ~1% (FDA PI).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Abdominal pain / cramps | 3–9% | Most common GI complaint; evaluate if persistent or worsening for ulcer development |
| Diarrhoea | 3–9% | More frequent at higher doses (150–200 mg/day); evaluate if bloody or persistent |
| Dyspepsia / indigestion | 3–9% | Co-prescribe PPI in patients with GI risk factors; lower than aspirin in comparative trials |
| Nausea | 3–9% | Take with food to minimise; consider potassium salt if enteric coating poorly tolerated |
| Headache | 3–9% | Common across all NSAID classes; rule out medication overuse headache with chronic use |
| Elevated liver enzymes | ~2–4% | AST >3× ULN in ~2% of 5,700 patients (AST only measured); ALT/AST elevations in ~4% of a separate 3,700-patient trial; >8× ULN in ~1%. Higher than other NSAIDs; check LFTs within 4–8 weeks; discontinue if persistent or symptomatic |
| Dizziness | 1–3% | Advise caution with driving at initiation |
| Peripheral edema | 1–3% | Monitor weight and BP; caution in heart failure |
| Rash / pruritus | 1–3% | Discontinue if progressive; evaluate for SJS/TEN |
| Tinnitus | 1–3% | Usually reversible with dose reduction; assess hearing if persistent |
| Increased bleeding time | 1–3% | Higher risk with concurrent anticoagulants or antiplatelet agents |
| Anaemia | 1–3% | May reflect occult GI blood loss; check Hb/Hct if fatigue or pallor |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Cardiovascular thrombotic events (MI, stroke) | RR 1.41 for major vascular events at 150 mg/day (CNT meta-analysis); comparable to coxib risk | First weeks; increases with dose and duration | Use lowest effective dose for shortest duration; avoid post-CABG; consider naproxen as alternative if CV risk is primary concern |
| GI bleeding, ulceration, perforation | ~1% at 3–6 months; 2–4% at 1 year (NSAID class) | Any time; without warning | Discontinue immediately; urgent endoscopy; add PPI prophylaxis in high-risk patients |
| Severe hepatotoxicity (fulminant hepatitis, liver necrosis, liver failure) | Rare (fulminant); LFT >3× ULN in ~2%; >8× ULN in ~1%; higher than other NSAIDs | Typically within first 2–6 months; can occur at any time | Monitor LFTs at baseline and within 4–8 weeks; discontinue immediately if ≥3× ULN or symptomatic; never rechallenge after severe reaction |
| Acute kidney injury / renal papillary necrosis | Uncommon; higher in dehydrated/elderly | Days to weeks | Discontinue; IV hydration; monitor creatinine |
| Severe skin reactions (SJS, TEN, DRESS, FDE) | Very rare | 1–8 weeks | Discontinue immediately; dermatology referral; permanent discontinuation |
| Anaphylactoid reactions | Very rare | Minutes to hours | Emergency management; permanent discontinuation |
| Heart failure exacerbation | ~2-fold increased hospitalisation (NSAID class) | Days to weeks | Avoid in severe HF; monitor fluid balance |
Diclofenac carries a higher hepatotoxicity risk than any other commonly used NSAID. In clinical trials, meaningful transaminase elevations (>3× ULN) occurred in ~2% of 5,700 patients. In a large 3,700-patient trial monitored at 8 and 24 weeks, ALT/AST elevations occurred in ~4% and marked elevations (>8× ULN) in ~1%. Rare cases of fulminant hepatitis, liver necrosis, and hepatic failure (some fatal) have been reported. The FDA PI specifically recommends measuring LFTs within 4–8 weeks of starting diclofenac, and exercising caution when co-prescribing with other potentially hepatotoxic drugs (e.g., acetaminophen, antibiotics, anti-epileptics).
Drug Interactions
Diclofenac is metabolised primarily by CYP2C9. When co-administered with aspirin, diclofenac’s protein binding is reduced, though the clinical significance is uncertain. Hepatic metabolism accounts for nearly 100% of elimination, making hepatotoxic co-medications a particular concern.
Monitoring
- Hepatic FunctionBaseline, 4–8 weeks, then periodically
RoutineALT/AST — CRITICAL for diclofenac. LFT elevations >3× ULN in ~2% of patients (higher than other NSAIDs). Monitor at baseline and within 4–8 weeks of initiation. Repeat at 24 weeks. Discontinue immediately if ≥3× ULN persistent or symptomatic. Also monitor if co-prescribing hepatotoxic drugs. - Blood PressureBaseline, then periodically
RoutineNSAIDs including diclofenac can elevate BP. Monitor more frequently in patients on antihypertensives. - Renal FunctionBaseline, then q6–12 months
RoutineSerum creatinine, BUN, eGFR. Although unchanged diclofenac is not renally eliminated, prostaglandin-dependent renal perfusion may be compromised. - CBCBaseline; then if signs of anaemia or bleeding
Trigger-basedMonitor Hb/Hct for occult GI blood loss; anaemia reported frequently in trials. - GI SymptomsEvery visit
RoutineAsk about dyspepsia, abdominal pain, dark stools. Low threshold for endoscopy if new symptoms. - CV SymptomsEvery visit
RoutineScreen for chest pain, dyspnoea, oedema. Diclofenac 150 mg/day carries CV risk comparable to coxibs (CNT meta-analysis RR 1.41).
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to diclofenac or any component, including anaphylaxis or serious skin reactions
- Aspirin-exacerbated respiratory disease (AERD) — aspirin triad (asthma, nasal polyps, aspirin sensitivity)
- Peri-operative CABG surgery setting
- Pregnancy ≥30 weeks gestation
- Active hepatic disease or significant hepatic impairment
Relative Contraindications (Specialist Input Recommended)
- Advanced renal disease — not recommended; may hasten renal dysfunction
- Active peptic ulcer or recent GI bleed — mandatory PPI if NSAID essential
- Severe heart failure (NYHA III–IV) — risk of decompensation
- Known CV disease or high CV risk — diclofenac carries higher CV risk than naproxen; consider alternative NSAID
- Pregnancy 20–30 weeks — limit use; risk of oligohydramnios
Use with Caution
- Elderly (≥65 years) — increased GI, CV, renal, and hepatic risk
- Concurrent hepatotoxic drugs — additive liver injury risk; monitor LFTs more frequently
- Concurrent anticoagulants, SSRIs, corticosteroids — additive bleeding risk
- Dehydration or hypovolaemia — correct volume status before starting
- Asthma without aspirin sensitivity — monitor for exacerbation
Cardiovascular Thrombotic Events: NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may begin early in treatment and increase with duration of use. Diclofenac is contraindicated in the setting of CABG surgery. The CNT Collaboration meta-analysis found diclofenac 150 mg/day to carry cardiovascular risk comparable to COX-2 selective inhibitors (RR 1.41).
Gastrointestinal Bleeding, Ulceration, and Perforation: NSAIDs cause an increased risk of serious GI adverse events which can be fatal. These events can occur at any time without warning. Elderly patients and those with prior peptic ulcer disease or GI bleeding are at greater risk.
Patient Counselling
Purpose of Therapy
Diclofenac reduces pain, swelling, and stiffness by blocking chemicals that cause inflammation. It is not a cure for arthritis but helps manage symptoms to improve daily functioning. It should be used at the lowest dose for the shortest time needed, and your liver function will be monitored with blood tests.
How to Take
Swallow enteric-coated tablets whole with water — do not crush or chew, as the coating protects your stomach. Take with food to reduce stomach upset. For Cambia (migraine powder), dissolve one packet in water and drink immediately. Do not combine with other NSAID products. Different brands and forms of diclofenac are not interchangeable.
Sources
- Voltaren (diclofenac sodium enteric-coated tablets) — Full Prescribing Information. Revised 2021. accessdata.fda.govPrimary source for oral diclofenac indications, dosing, hepatotoxicity data (2% AST >3× ULN in 5,700 patients; 4% ALT/AST and 1% >8× ULN in 3,700-patient trial), and adverse reactions.
- Voltaren Gel (diclofenac sodium topical gel 1%) — Full Prescribing Information. dailymed.nlm.nih.govSource for topical formulation data; systemic absorption ~6% of oral dose; documents non-interchangeability with oral formulations.
- Bhala N, Emberson J, Merhi A, et al. (CNT Collaboration). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9CNT meta-analysis: key source for diclofenac CV risk (RR 1.41 for major vascular events at 150 mg/day, comparable to coxibs); also established GI risk profile data.
- Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. doi:10.1056/NEJMoa1611593PRECISION trial: provides NSAID CV safety comparator context (diclofenac not directly studied but CNT findings inform its relative risk positioning).
- Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 2005;100(8):1685–1693. doi:10.1111/j.1572-0241.2005.41833.xLarge epidemiological study documenting NSAID-associated GI mortality; diclofenac among the most frequently implicated agents.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis. Arthritis Care Res. 2020;72(2):149–162. doi:10.1002/acr.24131Conditionally recommends oral NSAIDs including diclofenac for OA with appropriate GI and CV risk assessment.
- Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738. doi:10.1038/ajg.2009.115Key guideline for GI risk stratification and gastroprotective therapy in NSAID users.
- Menassé R, Hedwall PR, Kraetz J, et al. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol Suppl. 1978;22:5–16. PubMed: 98835Foundational pharmacological characterisation of diclofenac’s anti-inflammatory, analgesic, and antipyretic properties including COX inhibition kinetics.
- Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4’-hydroxylation in human liver. Life Sci. 1993;52(1):29–34. doi:10.1016/0024-3205(93)90285-BEstablishes CYP2C9 as the major enzyme for diclofenac 4′-hydroxylation, underpinning the metabolic basis for diclofenac hepatotoxicity risk.
- Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997;33(3):184–213. doi:10.2165/00003088-199733030-00003Definitive PK review covering bioavailability (~50%), V/F (1.4 L/kg), protein binding (>99%), half-life (~2 h), synovial fluid persistence, and hepatic metabolism dependence.
- Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-selective non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308. doi:10.1136/bmj.332.7553.1302Early meta-analysis establishing that diclofenac, like COX-2 inhibitors, carries elevated cardiovascular thrombotic risk compared to placebo.
- Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39(5):1430–1440. doi:10.1002/hep.20205Key study investigating the immunological mechanisms of diclofenac-specific hepatotoxicity, including reactive metabolite protein adduct formation.
- Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1988;35(3):244–285. doi:10.2165/00003495-198835030-00004Comprehensive early drug evaluation covering the full range of diclofenac formulations, clinical efficacy across rheumatological indications, and comparative safety profile.